ICICI Direct: Divi’s Labs Delivers Sturdy Q2 Numbers; More Capex For Better Visibility  

ICICI Direct: Divi’s Labs Delivers Sturdy Q2 Numbers; More Capex For Better Visibility

An employee checks capsules as they move along the production line. (Photographer Andrey Rudakov/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Divi’s Laboratories Ltd.’s revenues grew 21.0% YoY to Rs 1,749 crore (our estimate Rs 1,679 crore).

Generic segment grew 25.9% YoY to Rs 883 crore. Custom synthesis grew 18.1% YoY to Rs 700 crore. Carotenoids grew 9.9% YoY to Rs 167 crore.

Ebitda margins expanded 843 basis points YoY to 42.4% (our estimate 36.5%) due to significantly better gross margin performance and lower other expenditure.

Click on the attachment to read the full report:

ICICI Direct DivisLab Q2FY21 Result Update.pdf
Read Document

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Still Not convinced ?  Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
GET REGULAR UPDATES